0.73
-0.0205(-2.73%)
Currency In USD
| Previous Close | 0.75 |
| Open | 0.77 |
| Day High | 0.77 |
| Day Low | 0.71 |
| 52-Week High | 12.51 |
| 52-Week Low | 0.71 |
| Volume | 210,853 |
| Average Volume | 195,511 |
| Market Cap | 27.91M |
| PE | -3.47 |
| EPS | -0.21 |
| Moving Average 50 Days | 0.97 |
| Moving Average 200 Days | 1.88 |
| Change | -0.02 |
If you invested $1000 in FibroBiologics, Inc. Common Stock (FBLG) since IPO date, it would be worth $41.69 as of June 01, 2025 at a share price of $0.73. Whereas If you bought $1000 worth of FibroBiologics, Inc. Common Stock (FBLG) shares 6 months ago, it would be worth $269.19 as of June 01, 2025 at a share price of $0.73.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting
GlobeNewswire Inc.
May 16, 2025 12:30 PM GMT
HOUSTON, May 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for ch
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
May 14, 2025 8:30 PM GMT
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the third quarter of 2025HOUSTON, May 14, 2025 (GLOBE NEW
FibroBiologics Presents at the ThymUS 2025 Meeting
GlobeNewswire Inc.
Apr 29, 2025 1:15 PM GMT
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for